ResMed price target raised to $251 from $238 at KeyBanc

KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed to $251 from $238 and keeps an Overweight rating on the shares. KeyBanc was incrementally encouraged by overall fundamental progress, particularly around its gross margin trajectory for Q4 and FY25, the analyst tells investors in a research note.